Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 127.51B, Vertex Pharmaceuticals(VRTX) trades at $503.09. The stock has a price-to-earnings ratio of 29.36.
On 2026-10-05, Vertex Pharmaceuticals(VRTX) stock traded between a low of $496.15 and a high of $506.01. Shares are currently priced at $503.09, which is +1.4% above the low and -0.6% below the high.
Vertex Pharmaceuticals(VRTX) shares are trading with a volume of 216.01K, against a daily average of 999.87K.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $400.74 at its lowest and $560.25 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $400.74 at its lowest and $560.25 at its peak.
VRTX News
Biotechnology investors often compare the steady cash flows of established giants with the explosive potential of specialized innovators. Choosing between Amgen...
In the latest close session, Vertex Pharmaceuticals (VRTX Quick QuoteVRTX - Free Report) was down 3.07% at $506.74. The stock trailed the S&P 500, which r...
Bond markets are loud again. Government borrowing costs sit near multi decade highs, which makes every dollar of future cash flow work harder to justify its val...
Analyst ratings
77%
of 35 ratingsMore VRTX News
UBS raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $615 from $585 and keeps a Buy rating on the shares. Vertex’s key near-term catalyst is t...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.